Pegbin is a national Class 1 new drug independently developed by Xiamen Tebao Biotechnology. It is the first domestically produced long-acting interferon variety approved for marketing in my country. It holds multiple patents and has received long-term support from the country’s major new drug creation projects during the 11th and 12th Five-Year Plans. The Phase III hepatitis B clinical studies (820 cases) and the Phase III hepatitis C clinical studies (770 cases) of Pegbin are huge in scale. The results show that its efficacy and safety are the same as those of imported reference substances, and the rate of neutralizing antibody production is lower. Do you think it’s reliable?